INTRODUCTION

In the US, there are now more procedures involving ophthalmic injections than cataract surgeries performed annually. This is primarily driven by the advent of drugs that target vascular endothelial growth factor (VEGF) in the treatment of diseases such as:

- Age-related Macular Degeneration (AMD)
- Diabetic macular oedema (DME)
- Diabetic retinopathy (DR)
- Retinal vein occlusions
- Retinopathy of prematurity (ROP).

Other drugs are also used for treatment of eye infections (and the resulting endophthalmitis), uveitis and post-cataract prophylaxis. It is estimated that, in 2016, six million intravitreal injections were administered in the US alone. With an ageing population and increasing incidence of diabetes, the number of such injections is expected to continue to rise.

Currently, there are two commonly used, approved anti-VEGF agents – Eylea® marketed by Regeneron Pharmaceuticals (Tarrytown, NY, US) in the US, Bayer (Leverkusen, Germany) in Europe and Santen (Osaka, Japan) in Japan; and Lucentis®, marketed by Genentech (San Francisco, CA, US) in the US and Novartis (Basel, Switzerland) outside it. Eylea® and Lucentis® represented 26.3% of all Medicare Part B spending in 2016.1 Despite their relatively small unit volumes, these high-value drugs represent an important part of the healthcare system and have

Table 1: Injection dose stroke sensitivity.

<table>
<thead>
<tr>
<th></th>
<th>0.5 mL PFS</th>
<th>1 mL Long PFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Syringe Diameter (mm)</td>
<td>4.65</td>
<td>6.45</td>
</tr>
<tr>
<td>Dose Stroke Sensitivity (µL/mm)</td>
<td>17.0</td>
<td>32.7</td>
</tr>
</tbody>
</table>

“The typical dose volume for ophthalmic injections is 50 µL, but delivering such a small dose volume with a conventional hypodermic syringe or PFS is challenging.”

Dr Gautam N Shetty
Chief Executive Officer
T: +1 216 272 5521
E: GS@CongruenceMed.com

Congruence Medical Solutions, LLC
3000 Falls Road, Suite 200A
Baltimore
MD 21211
United States

www.microliterdose.com
drawn biosimilar interest. In addition to the anticipated biosimilar activity in this space, there are a number of novel drugs in the clinical development pipeline.

PREFILLED SYRINGES FOR OPHTHALMIC INJECTIONS

There are numerous benefits to using a prefilled syringe (PFS) for ophthalmic injections. The benefits of using a PFS include:

- Lower incidence of exogenous endophthalmitis arising from injection in the eye. Endophthalmitis is considered one of the most serious adverse events related to intravitreal injection, leading to blindness or even patient death. This lower occurrence rate may be attributed to there being fewer use-steps associated with a PFS.
- Reduction in syringe preparation time of 27–39%, which could provide a substantive benefit to clinicians, considering the increasing trend in number of injections administered.
- Mitigating reported risk from leachable-mediated intra-ocular inflammation, which is suspected to be associated with use of some hypodermic syringes. Presence of leachable silicone has resulted in several lawsuits (including class action) in the US, which could be addressed by employing either baked-on silicone or silicone-free PFS.
- Reducing drug fill volume (compared with a vial), potentially increasing effective drug product yield for a given drug stock solution.
- Reducing downstream packaging costs associated with injection kits, thereby streamlining supply-chain operations.

Novartis launched the Lucentis® PFS in 2014 and Genentech launched its own in 2017. Regeneron Pharmaceuticals has indicated a launch of a PFS for Eylea® in 2019. For biosimilars and other novel drugs in the development pipeline, PFS for ophthalmic injections shouldn’t be merely a consideration for product lifecycle management. Clinicians have indicated strong preference for prefilled delivery options.

CHALLENGES TO ACHIEVING ACCURATE, PRECISE MICROLITRE DOSES

The typical dose volume for ophthalmic injections is 50 µL, but delivering such a small dose volume with a conventional hypodermic syringe or PFS is challenging. The plunger travelling only a millimetre results in the dispensing of 17 µL and 32 µL, in 0.5 mL standard PFS and 1 mL long standard PFS, respectively (Table 1). Hence, any slight error or variation at start-of-dose or end-of-dose results in a disproportionate degree of inaccuracy. Setting a dose in a conventional system by aligning the plunger stopper with a marking on the syringe barrel tests the limits of human capability. Data from a user study involving retina specialists illustrates the limitation of a conventional PFS in this regard (Figure 1).

A syringe having an internal diameter smaller than that of a standard 0.5 mL PFS could potentially improve accuracy when delivering a microlitre sized dose. However, integration with standard pharmaceutical fill-finish infrastructure would be challenging with non-standard PFS systems. Any consideration for a non standard PFS would need significant capital investment in PFS component development and development of custom fill-finish equipment.

The same issue arises with the injection of a 50 µL dose using 1 cm³ hypodermic syringes, which are of a similar internal diameter to 0.5 mL PFS. This is widely reported in the literature and was highlighted in a presentation at the American Academy of Ophthalmology (AAO) meeting in Chicago, IL, US in October 2018. This inaccuracy and imprecision is reported not only between uses for the same user but also between users. It can be a significant issue for applications where the therapeutic window is extremely narrow, such as injections in pre-term neonates diagnosed with ROP. Additionally, accuracy and precision of the delivered dose are critical to the fidelity of clinical data used to measure drug effectiveness, for example in dose-ranging studies.

Chronic ocular diseases such as AMD and DME require regular intra-ocular injections, usually monthly. Frequent under-dosing could result in suboptimal clinical outcomes, whereas overdosing could result in complications, such as increased, sustained intra-ocular pressure (IOP) post-injection, requiring secondary interventions. It is therefore key to the treatment of such conditions to deliver the dose required accurately, every time.

CONGRUENCE MICROLITRE DOSING SYRINGE DEVICE

The Congruence MDS device consists of a dose-controlling plunger rod subassembly adapted to integrate with a standard 1 mL long PFS.

“The Congruence MDS platform consists of a dose-controlling plunger rod subassembly adapted to integrate with a standard 1 mL long PFS.”
long PFS. A prefilled, pre-set, single-use system is shown in Figure 2. The steps of use include:

- Attaching a needle
- Setting the dose (by rotating a dose dial)
- Depressing the plunger rod to inject.

In this variant, the dose is set at time of manufacturing and the user cannot set and deliver a different dose volume. Addition of the device subassembly to the filled PFS can be either manual or automated.

Depending on the application, the MDS platform can be modified to yield the following possible configurations:

- Prefilled and pre-set
- Prefilled and user-set
- User-filled and pre-set
- User-filled and user-set.

Both user-filled configurations allow a syringe integrated with the MDS to be packaged with a drug vial. The user-filled, user-set MDS configuration provides accurate and precise microlitre dosing with functionality equivalent to a conventional syringe. The MDS can also be customised to accommodate differences in drug viscosity, dose volume, look and feel, and PFS size/type. While the MDS can work with 0.5 mL PFS, compatibility with a 1 mL long PFS provides pharmaceutical and biotechnology companies a lot of flexibility, not only with PFS component sourcing but also with drug filling.

The inbuilt mechanical advantage of the MDS with a 1 mL long PFS enables delivery of a drug solution with viscosity of up to 100 cp with an injection force of less than 30 N when injecting through a 30G, half-inch long needle.

**USER EVALUATION OF THE MDS**

The MDS was evaluated by 30 retina specialists from the US, Europe, Japan and Latin America to demonstrate error-free use, in addition to accurate, precise microlitre delivery.

The MDS was evaluated by 30 retina specialists from the US, Europe, Japan and Latin America to demonstrate error-free use, in addition to accurate, precise microlitre delivery. The data compares favourably with data generated in the laboratory, illustrating that MDS performance is independent of the user. Other key highlights from the user evaluation included:

- 100% of the respondents were able to perform all steps of operation in an error-free manner.
- 87% of the respondents would prefer to use the MDS over other currently available options.
- 97% of the respondents indicated that they found the device comfortable to use.
- 90% of the respondents indicated that they found the device easy to use.
- The dose time was comparable with Lucentis® PFS.

The MDS with a 1 mL long PFS outperformed conventional hypodermic...
The MDS has been shown to be able to deliver a dose as low as 5 µL accurately (Figure 4) using a 1 mL long PFS. This capability allows for cost-effective dose-ranging studies. Pharmaceutical development requires demonstration of a dose-response. The drug material costs scale by the number of drug dose levels to be evaluated. The MDS can enable significant savings by requiring preparation of only one drug solution at its highest strength, with delivery of lower levels being achieved by adjusting the volume delivered. Previously, this was not possible because of the difficulty of reliably delivering accurate microlitre doses. Additionally, improving clinical trial design by modulating device-use parameters to ensure masking can easily be engineered with the MDS.

MDS PRESENT STATUS & FUTURE OUTLOOK

The MDS will be available for clinical evaluation and use in 2019. Congruence Medical Solutions is developing other technologies relevant to the delivery of pharmaceutical agents for ophthalmic applications. For example, a device for accurately and precisely injecting extremely viscous drug formulations (>1000 cp) with a standard PFS is under development. Additionally, Congruence has developed a device for preclinical applications to inject drug volumes as low as 0.5 µL accurately by extending the capability of the MDS.

ACKNOWLEDGEMENTS

The author would like to acknowledge the contributions from Lou Castanga, of CAE Consulting, and Lance Wetzel, Independent Consultant.

ABOUT THE COMPANY

Congruence Medical Solutions, LLC is a science-based, technical innovation company focused on the development and supply of ophthalmic drug delivery devices.

REFERENCES